BE553536A - - Google Patents
Info
- Publication number
- BE553536A BE553536A BE553536DA BE553536A BE 553536 A BE553536 A BE 553536A BE 553536D A BE553536D A BE 553536DA BE 553536 A BE553536 A BE 553536A
- Authority
- BE
- Belgium
- Prior art keywords
- antibiotic
- antibiotics
- oxytetracycline
- tetracycline
- weight
- Prior art date
Links
- 230000003115 biocidal Effects 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 40
- 229960000625 Oxytetracycline Drugs 0.000 claims description 21
- IWVCMVBTMGNXQD-PXOLEDIWSA-N Oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 21
- 239000004100 Oxytetracycline Substances 0.000 claims description 20
- 235000019366 oxytetracycline Nutrition 0.000 claims description 20
- 229960002180 Tetracycline Drugs 0.000 claims description 15
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 claims description 15
- 239000004098 Tetracycline Substances 0.000 claims description 15
- 235000019364 tetracycline Nutrition 0.000 claims description 15
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 claims description 9
- 229960004475 Chlortetracycline Drugs 0.000 claims description 9
- 235000019365 chlortetracycline Nutrition 0.000 claims description 9
- 239000004099 Chlortetracycline Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 description 22
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 19
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 19
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 19
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 19
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 19
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 19
- 229940079866 intestinal antibiotics Drugs 0.000 description 19
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 19
- 244000005700 microbiome Species 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- YJQPYGGHQPGBLI-KGSXXDOSSA-N Cathomycin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229960002950 Novobiocin Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000002195 synergetic Effects 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K Aluminium chloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- YJQPYGGHQPGBLI-HYFMXHDLSA-N NOVOBIOCIN Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-HYFMXHDLSA-N 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 229940072172 Tetracycline antibiotics Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 240000008371 Bacillus subtilis Species 0.000 description 1
- 229960003071 Bacitracin Drugs 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 229950005779 CARBOMYCIN Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L Dipotassium phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000186984 Kitasatospora aureofaciens Species 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- -1 S. aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000187419 Streptomyces rimosus Species 0.000 description 1
- 229940063650 Terramycin Drugs 0.000 description 1
- 206010046577 Urinary tract infection Diseases 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- FQVHOULQCKDUCY-OGHXVOSASA-N [(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(1S,3R,7R,8S,9S,10R,12R,14E,16S)-7-acetyloxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimeth Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@H]1[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@@H]2O[C@H]2C[C@@H](C)OC(=O)C[C@H]([C@@H]1OC)OC(C)=O)[C@H]1C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1 FQVHOULQCKDUCY-OGHXVOSASA-N 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005695 dehalogenation reaction Methods 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE553536A true BE553536A (de) |
Family
ID=178310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE553536D BE553536A (de) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE553536A (de) |
-
0
- BE BE553536D patent/BE553536A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1879655B1 (de) | Pharmazeutische Zusammensetzung mit einem antibakteriellen Mittel und einem aus Carveol, Carvacrol, Alpha-Ionone, Beta-Ionone und Thymol ausgewählten Wirkstoff | |
| JPH09501702A (ja) | 増強された抗生物質組成物 | |
| BE895724A (fr) | Nouvelle utilisation therapeutique de la dihydrocyclosporine d | |
| FR2628324A1 (fr) | Compositions pharmaceutiques antivirales et immunostimulantes et procede pour les preparer | |
| JPH11504937A (ja) | ジアルキルチアクミシン化合物 | |
| BE553536A (de) | ||
| CH646059A5 (fr) | Compositions antibiotiques contenant un macrolide et un aminoheteroside. | |
| JPH072672A (ja) | 抗菌性配合製剤 | |
| BE551953A (de) | ||
| FR2515516A1 (fr) | Composition pharmaceutique pour le traitement de la lithiase renale infectee contenant de l'acide propionohydroxamique ou ses sels acceptables en pharmacie | |
| FR2887249A1 (fr) | Compose d-glucopyranose 1-[3,5-bis(1,1-dimenthylethyl)-4- hydroxybenzoate] et ses derives, leur preparation et leurs utilisations | |
| Gordon et al. | Nystatin (Mycostatin®) Therapy in Experimental Coccidioidomycosis | |
| US5264216A (en) | Pharmaceutical uses of bilobalide and derivatives thereof and pharmaceutical compositions adapted for such use | |
| LU81968A1 (fr) | Sels d'argent d'acide phosphanilique,leur procede de production,composition antibacterienne les contenant et leur application a l'inhibition de la croissance des bacteries | |
| BE505709A (de) | ||
| MXPA02002791A (es) | Composicion farmaceutica que contiene eucalipto y aceite de naranja. | |
| CA2664124A1 (fr) | Nouvelle classe de composes derives de terpene a activite antibiotique, compositions les contenant et utilisations | |
| BE502262A (de) | ||
| BE818335R (fr) | Composition antibacterienne et procede | |
| EP1313500B1 (de) | Zusammensetzungen aus dalfopristin und quinupristin mit cefpirom | |
| BE825937A (fr) | Compositions antibacteriennes comprenant un compose de cephalosporine et un compose de penicilline | |
| BE556491A (de) | ||
| JP2001072596A (ja) | 抗菌作用の増強方法 | |
| BE571622A (de) | ||
| JPS62129217A (ja) | 医薬用殺菌組成物 |